BLAINJECTIONINJECTABLE
Approved
Sep 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMGALITY (galcanezumab-gnlm) is a monoclonal antibody developed by Eli Lilly approved in September 2018 for migraine prevention. It binds to calcitonin gene-related peptide (CGRP) ligand, a key neuropeptide involved in migraine pathophysiology. The drug is administered as a subcutaneous injection.
Peak
Peak lifecycle stage indicates mature commercial operations with established sales infrastructure and potential for optimization rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Emgality for Migraine in Breastmilk
Started Feb 2024
30 enrolled
Migraine
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Started Nov 2020
312 enrolled
Chronic Migraine
The Effect of Galcanezumab-gnlm on Post-Traumatic, Migrainous Headaches
Started Aug 2020
25 enrolled
Post-Traumatic Headache
Career Relevance
EMGALITY roles focus on commercial execution, market access, and field engagement in the competitive migraine prevention space. Peak lifecycle positioning offers stable career opportunities in brand management and field operations without the volatility of launch-phase roles.
Worked on EMGALITY at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.